Business Context and Reporting Period
This Form 6-K filing by Alpha Tau Medical Ltd. covers the month of March 2026. The report serves to disseminate a press release issued on March 31, 2026, regarding the company's clinical development activities.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report of a specific corporate event rather than a financial statement.
Material Changes
The primary material event reported is the first-ever oral presentation of data for the company's Alpha DaRT® technology in the context of pancreatic cancer. This presentation occurred at the Digestive Disease Week (DDW) 2026 conference.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard disclaimer that the information is furnished and not deemed "filed" under Section 18 of the Exchange Act. No unusual items or contingencies are detailed in the text provided.
Investor Verification Checklist
- Verify the specific clinical data and outcomes presented at DDW 2026 by reviewing the attached press release (Exhibit 99.1).
- Confirm the regulatory status and development timeline of the Alpha DaRT® platform for pancreatic cancer.
- Review the company's most recent Form 20-F or quarterly reports for actual financial performance metrics, as this filing contains none.